Loading clinical trials...
Loading clinical trials...
Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 With an Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis
Conditions
Interventions
APT-1011
Placebo oral tablet
+1 more
Locations
56
United States
Pinnacle Research Group, LLC
Anniston, Alabama, United States
Gut P.C., dba; Digestive Health Specialists of the Southeast
Dothan, Alabama, United States
East View Medical Research, LLC
Mobile, Alabama, United States
Del Sol Research Management, LLC
Tucson, Arizona, United States
Preferred Research Partners Inc.
Little Rock, Arkansas, United States
Arkansas Gastroenterology
North Little Rock, Arkansas, United States
Start Date
January 30, 2020
Primary Completion Date
May 5, 2022
Completion Date
October 24, 2022
Last Updated
June 12, 2023
NCT07112378
NCT06693531
NCT05199532
NCT06596252
NCT06443346
NCT06389994
Lead Sponsor
Ellodi Pharmaceuticals, LP
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions